125 related articles for article (PubMed ID: 8147235)
1. Efficacy, cycle control and side-effects of two monophasic combination oral contraceptives: gestodene/ethinylestradiol and norgestimate/ethinylestradiol.
Affinito P; Monterubbianesi M; Primizia M; Regine V; Di Carlo C; Farace MJ; Petrillo G; Nappi C
Gynecol Endocrinol; 1993 Dec; 7(4):259-66. PubMed ID: 8147235
[TBL] [Abstract][Full Text] [Related]
2. Comparison of two monophasic oral contraceptives: gestodene/ethinyl estradiol versus desogestrel/ethinyl estradiol.
Benagiano G
Int J Fertil; 1989 Sep; 34 Suppl():31-9. PubMed ID: 2576255
[TBL] [Abstract][Full Text] [Related]
3. Clinical comparison of two low-dose oral contraceptives, Minulet and Mercilon, in women over 30 years of age.
Kirkman RJ; Pedersen JH; Fioretti P; Roberts HE
Contraception; 1994 Jan; 49(1):33-46. PubMed ID: 8137624
[TBL] [Abstract][Full Text] [Related]
4. A clinical overview of a new triphasic contraceptive containing gestodene.
Christie T
Int J Fertil; 1989 Sep; 34 Suppl():40-9. PubMed ID: 2576257
[TBL] [Abstract][Full Text] [Related]
5. Cycle control, safety and efficacy of a 24-day regimen of gestodene 60 microg/ ethinylestradiol 15 microg and a 21-day regimen of desogestrel 150 microg/ethinylestradiol 20 microg.
Eur J Contracept Reprod Health Care; 1999 Nov; 4 Suppl 2():17-25. PubMed ID: 14677621
[TBL] [Abstract][Full Text] [Related]
6. Multicenter trial of two monophasic oral contraceptives containing 30 mcg ethinylestradiol and either desogestrel or gestodene in Thai women.
Koetsawang S; Charoenvisal C; Banharnsupawat L; Singhakovin S; Kaewsuk O; Punnahitanont S
Contraception; 1995 Apr; 51(4):225-9. PubMed ID: 7796587
[TBL] [Abstract][Full Text] [Related]
7. Comparison of efficacy, cycle control, and tolerability of two low-dose oral contraceptives in a multicenter clinical study.
Endrikat J; Düsterberg B; Ruebig A; Gerlinger C; Strowitzki T
Contraception; 1999 Nov; 60(5):269-74. PubMed ID: 10717778
[TBL] [Abstract][Full Text] [Related]
8. A twelve-month comparative clinical investigation of two low-dose oral contraceptives containing 20 micrograms ethinylestradiol/75 micrograms gestodene and 30 micrograms ethinylestradiol/75 micrograms gestodene, with respect to efficacy, cycle control, and tolerance.
Endrikat J; Müller U; Düsterberg B
Contraception; 1997 Mar; 55(3):131-7. PubMed ID: 9115000
[TBL] [Abstract][Full Text] [Related]
9. Metabolic profile of six oral contraceptives containing norgestimate, gestodene, and desogestrel.
Teichmann A
Int J Fertil Menopausal Stud; 1995; 40 Suppl 2():98-104. PubMed ID: 8574257
[TBL] [Abstract][Full Text] [Related]
10. Clinical experience with a new norgestimate-containing oral contraceptive.
Huber J
Int J Fertil; 1991; 36 Suppl 1():25-31. PubMed ID: 1678378
[TBL] [Abstract][Full Text] [Related]
11. Clinical and hormonal effects of ethinylestradiol combined with gestodene and desogestrel in young women with acne vulgaris.
Mango D; Ricci S; Manna P; Miggiano GA; Serra GB
Contraception; 1996 Mar; 53(3):163-70. PubMed ID: 8689881
[TBL] [Abstract][Full Text] [Related]
12. Clinical tolerance of a combined monophasic contraceptive agent containing a low-dose of ethinyloestradiol and gestodene in adolescents.
Leonard F; Gaspard U; Theunissen L
Curr Med Res Opin; 1993; 13(2):78-86. PubMed ID: 8325045
[TBL] [Abstract][Full Text] [Related]
13. Open, multicenter comparison of efficacy, cycle control, and tolerability of a 23-day oral contraceptive regimen with 20 microg ethinyl estradiol and 75 microg gestodene and a 21-day regimen with 20 microg ethinyl estradiol and 150 microg desogestrel.
Endrikat J; Cronin M; Gerlinger C; Ruebig A; Schmidt W; Düsterberg B
Contraception; 2001 Sep; 64(3):201-7. PubMed ID: 11704101
[TBL] [Abstract][Full Text] [Related]
14. Effect of two oral contraceptives containing ethinyl estradiol and gestodene or norgestimate on different lipid and lipoprotein parameters.
Wiegratz I; Jung-Hoffmann C; Gross W; Kuhl H
Contraception; 1998 Aug; 58(2):83-91. PubMed ID: 9773262
[TBL] [Abstract][Full Text] [Related]
15. Comparative profiles of reliability, cycle control and side effects of two oral contraceptive formulations containing 150 micrograms desogestrel and either 30 micrograms or 20 micrograms ethinyl oestradiol.
Akerlund M; Røde A; Westergaard J
Br J Obstet Gynaecol; 1993 Sep; 100(9):832-8. PubMed ID: 8218004
[TBL] [Abstract][Full Text] [Related]
16. Multicenter trial of a monophasic oral contraceptive containing ethinyl estradiol and desogestrel.
Rekers H
Acta Obstet Gynecol Scand; 1988; 67(2):171-4. PubMed ID: 2972160
[TBL] [Abstract][Full Text] [Related]
17. Clinical comparative study of oral contraceptives containing 30 microg ethinylestradiol/150 microg levonorgestrel, and 35 microg ethinylestradiol/250 microg norgestimate in Thai women.
Tantbirojn P; Taneepanichskul S
Contraception; 2002 Dec; 66(6):401-5. PubMed ID: 12499031
[TBL] [Abstract][Full Text] [Related]
18. Clinical and metabolic effects of gestodene and levonorgestrel.
Rabe T; Runnebaum B; Kohlmeier M; Harenberg J; Weicker H
Int J Fertil; 1987; 32 Suppl():29-44. PubMed ID: 2906345
[TBL] [Abstract][Full Text] [Related]
19. Investigation of the influence of two low-dose monophasic oral contraceptives containing 20 micrograms ethinylestradiol/75 micrograms gestodene and 30 micrograms ethinylestradiol/75 micrograms gestodene, on lipid metabolism in an open randomized trial.
Brill K; Then A; Beisiegel U; Jene A; Wünsch C; Leidenberger F
Contraception; 1996 Nov; 54(5):291-7. PubMed ID: 8934063
[TBL] [Abstract][Full Text] [Related]
20. Effect of two oral contraceptives containing ethinylestradiol and gestodene or norgestimate upon androgen parameters and serum binding proteins.
Wiegratz I; Jung-Hoffmann C; Kuhl H
Contraception; 1995 Jun; 51(6):341-6. PubMed ID: 7554973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
